An analysis of the medical records of patients treated at Massachusetts General Hospital (MGH) for an often-mysterious condition involving damage to small nerve fibers supports the hypothesis that some cases are caused by autoimmune disease and also identifies the first effective treatment option. This report on 55 patients diagnosed with what appears to be autoimmune small-fiber polyneuropathy (SFPN) finds that treatment with intravenous immunoglobulin, used to treat other autoimmune and inflammatory conditions, provided symptom relief and improved nerve function for most patients, allowing some to discontinue treatment.
“This is a proof-of-concept finding that dampening the body’s immune system may be safe and effective for treating apparently autoimmune SFPN, a condition that most patients don’t even know they have,” says Anne Louise Oaklander, MD, PhD, director of the
Nerve Unit in the MGH
Department of Neurology and the senior author of a paper receiving advance online publication in
Therapeutic Advances in Neurological Disorders. “This is the first treatment that has the potential to actually improve the nerve damage, not just block symptoms with drugs such as opioids that don’t address its cause.”
SFPN involves widespread damage to the tiny nerve fibers that carry pain signals and control internal functions such as heart rate, blood pressure and sweating. Patients often develop chronic pain, fatigue, weakness or fainting when standing, rapid heart rate or gastrointestinal problems. Common causes of SFPN include diabetes and chemotherapy-induced nerve damage, but this paper studied some of the 30 to 50 percent in whom no cause is found when they are first evaluated, leading to a diagnosis of “idiopathic” SFPN. Studies from Oaklander’s group and others have suggested that some such patients have a previously undiscovered autoimmune condition.